Key Dates

Related Announcements

•  October 19, 2023 - Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required). See NOFO RFA-NS-24-013.

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this Notice is to inform applicants of a change in receipt date for RFA-NS-24-013. Specifically, the single date of receipt for applications to this NOFO changes from February 20, 2024, to May 20, 2024.  Letters of intent are requested by March 20, 2024. Advisory Council review will take place in February 2025 and the earliest award start date will be March 2025.

Changes are reflected in italics.

Currently Reads:

Part 1. Overview

Key Dates

Posted Date

October 19, 2023

Open Date (Earliest Submission Date)

January 20, 2024

Letter of Intent Due Date(s)

January 20, 2024

Expiration Date February 21, 2024

Modified to Read:

Part 1. Overview

Key Dates

Posted Date

October 19, 2023

Open Date (Earliest Submission Date)

April 20, 2024

Letter of Intent Due Date(s)20

March 20, 2024

Expiration Date May 21, 2024

No other changes to this NOFO.

Inquiries

Please direct all inquiries to:

Rebecca Hommer, MD

National Institute of Neurological Disorders and Stroke (NINDS)

Telephone: 301-827-2257

E-mail: rebecca.hommer@nih.gov